Market Overview

UPDATE: Piper Jaffray Downgrades AtriCure from Overweight to Neutral


Piper Jaffray downgraded AtriCure (NASDAQ: ATRC) from an Overweight rating to a Neutral rating and lowered its price target from $12 to $6.

Piper Jaffray commented, “While the business at AtriCure performed well during Q2 with revenues of $18.3M (+8.9%, 10.5%cc) exceeding consensus expectations of $18.0M, the surprise and apparently sudden resignation of CEO David Drachman after 10 years at the company was the clear headliner. Considering ATRC was arguably at the brink of a positive inflection point in the company's history, Drachman's departure following the CFO departure last quarter gives us pause. Given the executive departures, suspension of guidance and uncertainty around the near-term direction of the company we downgrade ATRC shares to Neutral and lower our PT to $6 (1.5x EV/CY13E sales of $76M).”

AtriCure closed at $8.10 on Thursday.


Related Articles (ATRC)

View Comments and Join the Discussion!

Posted-In: Piper JaffrayAnalyst Color Downgrades Analyst Ratings

Latest Ratings

WKHSRoth CapitalMaintains15.0
HCKTRoth CapitalMaintains22.0
ARECRoth CapitalInitiates Coverage On7.5
SLABWells FargoMaintains180.0
PENWells FargoMaintains310.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at